Trastuzumab deruxtecan (T-DXd) is the second ADC to be approved for metastatic HER2+ breast cancer but differs from T-DM1 due to a cleavable topoisomerase I inhibitor intended to act on both HER2+ and nearby cells. Here, ERBB2 is linked to breast carcinoma.